Xeris Biopharma Holdings (XERS) Other Non Operating Income (2020 - 2026)

Xeris Biopharma Holdings has reported Other Non Operating Income for 7 years, with the latest figure at -$5.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Non Operating Income rose 7.31% year-over-year to -$5.7 million; the trailing twelve-month figure through Mar 2026 stood at $448000.0 (up 101.78% YoY), and the FY2024 full-year result was -$23.5 million, down 726.86% from the prior year.
• Other Non Operating Income for Q1 2026 stood at -$5.7 million, down from $18.6 million in the prior quarter.
• The five-year high for Other Non Operating Income was $18.6 million in Q4 2025, with the low at -$7.6 million in Q2 2022.
• Historically, Other Non Operating Income has averaged -$3.4 million across 5 years, with a median of -$5.0 million in 2022.
• Annual changes were most pronounced in 2022 — Other Non Operating Income plunged 340.28% — and 2025, when it soared 374.59%.
• Xeris Biopharma Holdings' Other Non Operating Income stood at $1.9 million in 2022, then slumped by 247.21% to -$2.8 million in 2023, then plunged by 142.57% to -$6.8 million in 2024, then soared by 374.59% to $18.6 million in 2025, then tumbled by 130.47% to -$5.7 million in 2026.
• The last three Other Non Operating Income figures came in at -$5.7 million (Q1 2026), $18.6 million (Q4 2025), and -$6.1 million (Q3 2025), per Business Quant data.